Enantiomer Effects of Huperzine A on the Aryl Acylamidase Activity of Human Cholinesterases
- 64 Downloads
1. Acetylcholinesterase (AChE, EC 126.96.36.199) and butyrylcholinesterase (BuChE, EC 188.8.131.52) are serine hydrolase enzymes that catalyze the hydrolysis of acetylcholine.
2. (−) Huperzine A is an inhibitor of AChE and is being considered for the treatment of Alzheimer's disease.
3. In addition to esterase activity, AChE and BuChE have intrinsic aryl acylamidase activity.
4. The function of aryl acylamidase is unknown but has been speculated to be important in Alzheimer pathology.
5. Kinetic effects of (−) huperzine A and ( ±)$ huperzine A on the aryl acylamidase activity of human cholinesterases were examined.
6. (−) Huperzine A inhibited the aryl acylamidase activities of both AChE and BuChE.
7. (±) Huperzine A inhibited this function in AChE but stimulated BuChE aryl acylamidase suggesting that the (+) enantiomer is a powerful activator of this enzyme activity.
8. The two huperzine enantiomers may prove to be useful tools to examine the function of aryl acylamidase activity, including its role in Alzheimer pathology.
Unable to display preview. Download preview PDF.
- Ariel, N., Ordentlich, A., Barak, D., Bino, T., Velan, B., and Shafferman, A. (1998). The ‘aromatic patch’ of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors. Biochem. J. 335:95–102.Google Scholar
- Ashani, Y., Grunwald, J., Kronman, C., Velan, B., and Shafferman, A. (1994). Role of tyrosine 337 in the binding of huperzine A to the active site of human acetylcholinesterase. Mol. Pharmacol. 45:555–560.Google Scholar
- Ashani, Y., Peggins, J. O., III, and Doctor, B. P. (1992). Mechanism of inhibition of cholinesterases by huperzine A. Biochem. Biophys. Res. Commun. 184:719–726.Google Scholar
- Ayer, W. A., Browne, L. M., Orszanska, H., Valenta, Z., and Liu, J.-S. (1989). Alkaloids of Lycopodium selago. On the identity of selagine with huperzine A and the structure of a related alkaloid. Can. J. Chem. 67:1538–1540.Google Scholar
- Bai, D. L., Tang, X. C., and He, X. C. (2000). Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr. Med. Chem. 7:355–374.Google Scholar
- Ballard, C. G. (2002). Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition. Eur. Neurol. 47:64–70.Google Scholar
- Bartus, R.T. (2000). On neurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163:495–529.Google Scholar
- Bartus, R. T., Dean, R. L. I., Beer, B., and Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–417.Google Scholar
- Costagli, C., and Galli, A. (1998). Inhibition of cholinesterase-associated aryl acylamidase activity by anticholinesterase agents: Focus on drugs potentially effective in Alzheimer's disease. Biochem. Pharmacol. 55:1733–1737.Google Scholar
- Coyle, J. T., Price, D. L., and DeLong, M. R. (1983). Alzheimer's disease: A disorder of cortical cholinergic innervation. Science 219:1184–1190.Google Scholar
- Darvesh, S., Kumar, R., Roberts, S., Walsh, R., and Martin, E. (2001). Butyrylcholinesterase-mediated enhancement of the enzymatic activity of trypsin. Cell. Mol. Neurobiol. 21:285–289.Google Scholar
- Darvesh, S., Walsh, R., and Martin, E. (2002). Enantiomer-specific inhibition of cholinesterases by huperzine A: 8th International Conference on Alzheimer's disease and related disorders in Stockholm, Sweden. Neurobiol. Aging 23:S113.Google Scholar
- Ellman, G. L., Courtney, K. D., Andres, V. J., and Featherstone, R. M. (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:88–95.Google Scholar
- Francis, P. T., Palmer, A. M., Snape, M., and Wilcock, G. K. (1999). The cholinergic hypothesis of Alzheimer's disease: A review of progress. J. Neurol. Neurosurg. Psychiatry 66:137–147Google Scholar
- Fujimoto, D. (1976). Serotonin-sensitive aryl acylamidase activity of acetylcholinesterase. FEBS Lett. 71:121–123.Google Scholar
- George, S. T., and Balasubramanian, A. S. (1982). The aryl acylamidases and their relationship to cholinesterases in human serum, erythrocyte and liver. Eur. J. Biochem. 121%:177–186.Google Scholar
- Giacobini, E. (2000). Cholinesterase inhibitors: From the Calabar bean to Alzheimer therapy. In Giacobini, E. (ed.), Cholinesterases and Cholinesterase Inhibitors, Martin Dunitz, London, pp. 181–226.Google Scholar
- Greig, N. H., Utsuki, T., Yu, Q., Zhu, X., Holloway, H. W., Perry, T., Lee, B., Ingram, D. K., and Lahiri, D. K. (2001). A new therapeutic target in Alzheimer's disease: Attention to butyrylcholinesterase. Curr. Med. Res. Opin. 17:159–165.Google Scholar
- Grutzendler, J., and Morris, J. C. (2001). Cholinesterase inhibitors for Alzheimer's disease. Drugs 61:41–52.Google Scholar
- Guillozet, A. L., Smiley, J. F., Mash, D. C., and Mesulam, M. M. (1997). Butyrylcholinesterase in the life cycle of amyloid plaques. Ann. Neurol. 42:909–918.Google Scholar
- Krall, W. J., Sramek, J. J., and Cutler, N. R. (1999). Cholinesterase inhibitors: A therapeutic strategy for Alzheimer disease. Ann. Pharmacother. 33:441–450.Google Scholar
- Liu, J. S., Zhu, Y. L., Yu, C. M., Zhou, Y. Z., Han, Y. Y., Wu, F. W., and Qi, B. F. (1986). The structures of huperzine A and B, two new alkaloids exhibiting anticholinesterase activity. Can. J. Chem. 64%:837–841.Google Scholar
- McKinney, M., Miller, J. H., Yamada, F., Tuckmantel, W., and Kozikowski, A. P. (1991). Potencies and stereoselectivities of enantiomers of huperzine A for inhibition of rat cortical acetylcholinesterase. Eur. J. Pharmacol. 203:303–305.Google Scholar
- Mesulam, M. M., and Geula, C. (1994). Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann. Neurol. 36:722–727.Google Scholar
- Op Den Velde, W., and Stam, F. C. (1976). Some cerebral proteins and enzyme systems in Alzheimer's presenile and senile dementia. J. Am. Geriatr. Soc. 24:12–16.Google Scholar
- Perry, E. K., Perry, R. H., Blessed, G., and Tomlinson, B. E. (1978). Changes in brain cholinesterases in senile dementia of the Alzheimer type. Neuropathol. Appl. Neurobiol. 4:273–277.Google Scholar
- Saxena, A., Redman, A. M., Jiang, X., Lockridge, O., and Doctor, B. P. (1997). Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 36:14642–14651.Google Scholar
- Silver, A. (1974). The Biology of Cholinesterases, Elsevier, Amsterdam.Google Scholar
- Valenta, Z., Yoshimura, H., Rogers, E. F., Ternbah, M., and Wiesner, K. (1960). The structure of selagine. Tetrahedron Lett. 10%:26–33.Google Scholar
- Wang, Y. E., Yue, D. X., and Tang, X. (1986). Anti-cholinesterase activity of huperzine A. Acta Pharmachol. Sinica 7:110–113.Google Scholar
- Yoshimura, H., Valenta, Z., and Wiesner, K. (1960). A rigorous proof of the selagine structure. Tetrahedron Lett. 12:14–17.Google Scholar